Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions ... to advancements in Allurion's proprietary Balloon technology, particularly improving the precision ...

Allurion Technologies (ALUR) announced that it has received an Issue Notification from the U.S. Patent and Trademark Office USPTO dated January ...

tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market. The company announced it would begin a study to see if ...

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

The Virtual Care Suite is also offered separately to providers to customize and manage weight-loss therapy for patients, regardless of their treatment plan. The Allurion Balloon is currently ...

It seeks to establish this mix as a standard for treatment of obesity. Along with a Virtual Care Suite that provide tools for healthcare professionals to monitor and modify treatments, the Allurion ...

and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and ...

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an ...